To investigate the consequences of G9a inhibition on the Sox9/β‐catenin/Myc axis in HCC, cells were treated with varying doses of G9a inhibitor, UNC0642, and at varying time points. This evidence concerns the gene MYC and hepatocellular carcinoma.